Please assess the completion status of the following clinical trial:

Trial Title: Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as Secondary Sjogren syndrome according to the 2002 American European consensus group (AECG) criteria, which require the presence of well defined major connective tissue disease (such as rheumatoid arthritis and systemic lupus erythematosus.~* All patients show chronic symptoms of burning, foreign body sensation, itching in both eyes, abnormal Schirmer test \<5 mm wetting of the paper after 5 minutes, and abnormal tear breakup time (TBUT) \< 10 seconds.~* Wash out period of 30 days before start of the immunomodulatory eye drops included in the investigator's study~Exclusion Criteria:~1. Any inflammation or active structural changes in the iris or anterior chamber.~2. Patients receiving or who had received systemic cyclosporine or tacrolimus.~3. Patients receiving any systemic drug that can cause dry eye as some antidepressants , antihistaminic drugs , hormonal therapy...etc~4. Glaucoma.~5. Previous ocular surgery.~6. Use of any topical medication other than artificial tears.~7. Contact lens wearers.~8. Presence of any corneal infection.~9. Any corneal diseases (ulcer, opacity, scar, bullous keratopathy, symblepharon or tumors).~10. Deforming structural lid or conjunctival abnormality.~11. Pregnancy.~12. Prior diagnosis of any of the following conditions would exclude participation in AECG study :~Past head and neck radiation treatment Hepatitis C infection Acquired immunodeficiency disease (AIDS) Pre-existing lymphoma Sarcoidosis Graft versus host disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporins 0.05 % treated eyes (Type: ACTIVE_COMPARATOR): Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
- Tacrolimus 0.03% treated eyes (Type: ACTIVE_COMPARATOR): Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).